Pharma Foods International (2929) Fundamentals 2026 — P/E 40.2x, Revenue Analysis | SniperIQ
Pharma Foods International (2929) is a JP-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥17.2B, trading at ¥592.00 on the JPX. This SniperIQ fundamentals page covers Pharma Foods International's valuation (P/E 40.2x, P/B 1.7x), profitability (net margin 0.6%), revenue (¥65.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Pharma Foods International's market cap?
Pharma Foods International (2929) has a market capitalization of approximately ¥17.2B, trading at ¥592.00 on the JPX. Market cap moves with the live share price.
What is Pharma Foods International's P/E ratio?
Pharma Foods International's trailing twelve-month P/E ratio is 40.2x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Pharma Foods International?
Pharma Foods International runs a net profit margin of 0.6%, a gross margin of 80.6%, and an operating margin of 1.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Pharma Foods International generate?
Pharma Foods International reported revenue of ¥65.3B for fiscal year 2025, with net income of ¥368M and earnings per share (EPS) of 12.8. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Pharma Foods International pay a dividend?
Pharma Foods International offers a trailing dividend yield of about 4.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Pharma Foods International financially healthy?
Pharma Foods International carries a debt-to-equity ratio of 1.71x and a current ratio of 1.04x, with a market beta of 0.89. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Pharma Foods International a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Pharma Foods International (2929) the key facts are: market cap ¥17.2B, P/E 40.2x, revenue ¥65.3B, 52-week range 513-1064. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Pharma Foods International's full fundamentals live
Get Pharma Foods International's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.